Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The study evaluate the addition of Irinotecan in neoadjuvant chemoradiation. Half of
participants will receive capecitabine alone together with neoadjuvant CRT, followed by a
cycle of XELOX, while the other will receive capecitabine and irinotecan during CRT, followed
by a cycle of XELIRI. All participants will be scheduled to receive surgery 6-8 weeks after
the completion of CRT, then 5 cycles of adjuvant chemotherapy of XELOX.
Phase:
Phase 3
Details
Lead Sponsor:
Fudan University
Collaborators:
First Affiliated Hospital of Chongqing Medical University Hubei Cancer Hospital Ruijin Hospital The First Affiliated Hospital with Nanjing Medical University